公开(公告)号：EP1117421A2

公开(公告)日：2001-07-25

申请号：EP99945967.0

申请日：1999-10-05

申请人： M & E Biotech A/S

发明人： STEINAA, Lucilla ,  MOURITSEN, Soren ,  NIELSEN, Klaus, Gregorius ,  HAANING, Jesper ,  LEACH, Dana ,  DALUM, Iben ,  GAUTAM, Anand ,  RASMUSSEN BIRK, Peter ,  KARLSSON, Gunilla

IPC分类号： A61K38/17 ,  A61K38/18 ,  C07K14/50 ,  C07K14/705 ,  C07K14/71 ,  C12N15/63 ,  C12N5/16 ,  C12N15/12

CPC分类号： C07K16/3069 ,  A61K39/0011 ,  C07K14/50 ,  C07K14/705 ,  C07K14/70539 ,  C07K14/71 ,  C07K2317/34 ,  C12N2799/021 ,  Y02A50/412

摘要： A method is disclosed for inducing cell-mediated immunity against cellular antigens. More specifically, the invention provides for a method for inducing cytotoxic T-lymphocyte immunity against weak antigens, notably self-proteins. The method entails that antigen presenting cells are induced to present at least one CTL epitope of the weak antigen and at the same time presenting at least one foreign T-helper lymphocyte epitope. In a preferred embodiment, the antigen is a cancer specific antigen, e.g. PSM, Her2, or FGF8b. The method can be exercised by using traditional polypeptide vaccination, but also by using live attenuated vaccines or nucleic acid vaccination. The invention furthermore provides immunogenic analogues of PSM, Her2 and FGF8b, as well as nucleic acid molecules encoding these analogues. Also vectors and transformed cells are disclosed. The invention also provides for a method for identification of immunogenic analogues of weak or non-immunogenic antigens.

公开(公告)号：EP0752886B1

公开(公告)日：1998-01-28

申请号：EP94926106.9

申请日：1994-08-25

申请人： M&E BIOTECH A/S

发明人： MOURITSEN, Soren ,  ELSNER, Henrik

IPC分类号： A61K39/00 ,  A61K39/385 ,  C07K19/00

CPC分类号： C07K14/00 ,  A61K39/00 ,  C07K14/525 ,  C07K14/77 ,  C07K2319/00

摘要： A novel method for utilizing the immune apparatus to remove and/or down-regulate self-proteins consists in inserting one or more foreign T-cell epitopes in such proteins by molecular biological means, thereby rendering said proteins immunogenic. The modulated self-proteins can be used as autovaccines against undesirable proteins in humans or animals, said autovaccine being useful as vaccines against a number of diseases, e.g. cancer, chronic inflammatory diseases, rheumatoid arthritis, inflammatory bowel diseases, allergic symptoms or diabetes mellitus.